ライフサイエンスコーパス: propylthiouracil

1 ylthiocarbamide and P = 3.96 x 10-19 for 6-n-propylthiouracil).

2 s (thiamazole [methimazole], carbimazole, or propylthiouracil).

3 nvironmental trigger is the antithyroid drug propylthiouracil.

4 ecially following exposure to hydralazine or propylthiouracil.

5 thyroidectomy and subsequent treatment with propylthiouracil.

6 hydralazine and 3 (10%) had been exposed to propylthiouracil.

7 reaction is insensitive to inhibition by 6-n-propylthiouracil.

8 ds contained low Km D2 activity resistant to propylthiouracil (1 mM) or to inactivation by N-bromoace

9 restriction, we modeled the binding mode of propylthiouracil, a weak inhibitor of CYB5R3 (IC50 = app

10 5% CI, 6.4%-10.7%) of patients who initiated propylthiouracil and 6.3% (46 of 727; 95% CI, 4.6%-8.1%)

11 f the mutants to the selective D1 inhibitors propylthiouracil and aurothioglucose were unaltered.

12 rminants of the sensitivity of the enzyme to propylthiouracil and aurothioglucose.

13 necrosis factor (TNF) drugs, oncology drugs, propylthiouracil and interferons.

14 Hydralazine, minocycline, propylthiouracil and levamisole-adulterated cocaine use

15 is, with high mortality, and is treated with propylthiouracil and methimazole.

16 rge to hospice between patients treated with propylthiouracil and those treated with methimazole, ass

17 ch as low K(m) (T(4)), 1.3 nm, resistance to propylthiouracil, and a short half-life ( approximately

18 uorescence pattern (pANCA) when treated with propylthiouracil, and changed back to anti-PR3 antibodie

19 ensitivity were assessed with ratings of 6-n-propylthiouracil, and covaried from all analyses.

20 , after the induction of hypothyroidism with propylthiouracil, and in response to T(3) administration

21 d the prevalence of exposure to hydralazine, propylthiouracil, and other drugs previously implicated

22 ve been reports suggesting that hydralazine, propylthiouracil, and several other drugs may cause some

23 The patient was managed with propylthiouracil, beta-blockers and digoxin.

24 ediated bitterness of phenylthiocarbamide or propylthiouracil, but now it encompasses additional phen

25 casionally teratogenic; and the alternative--propylthiouracil--can be hepatotoxic.

26 Ca(2+) responses were unaffected by 6-n-propylthiouracil, consistent with the expression of an u

27 days of maternal goitrogen treatment (10 ppm propylthiouracil) during the perinatal period (GD19-PN2)

28 ts that treatment with either hydralazine or propylthiouracil is associated with ANCA-positive vascul

29 l of 1383 patients (656 [47.4%] treated with propylthiouracil; mean [SD] age, 45 [16] years; 473 wome

30 ypical tastants (phenylthiocarbamide and 6-n-propylthiouracil, NaCl, sucrose, monopotassium glutamate

31 Patients received either propylthiouracil or methimazole for treatment of thyroid

32 , treatment with anti-thyroid hormone drugs (propylthiouracil or methimazole) completely rescues SMRT

33 rse events in patients who were treated with propylthiouracil or methimazole.

34 Tenth Revision codes and treated with either propylthiouracil or methimazole.

35 Thus, current guidelines recommending propylthiouracil over methimazole for treatment of thyro

36 Some guidelines recommend propylthiouracil over methimazole, although the differen

37 variation in bitter taste perception of 6-n-propylthiouracil (PROP) and structurally similar compoun

38 Taste blindness to the bitterness of 6-n-propylthiouracil (PROP) has been associated with increas

39 y to taste phenylthiocarbamide (PTC) and 6-n-propylthiouracil (PROP) is a polymorphic trait mediated

40 bitter taste of phenylthiocarbamide and 6-n-propylthiouracil (PROP) is a well-studied human trait.

41 tion in sensitivity to the bitterness of 6-n-propylthiouracil (PROP) is thought to play a role in the

42 HCl, caffeine, sucrose octaacetate (SOA) and propylthiouracil (PROP) solutions were examined in 1457

43 t, by sensitivity to the bitter taste of 6-n-propylthiouracil (Prop), a heritable trait.

44 s, such as phenylthiocarbamide (PTC) and 6-n-propylthiouracil (PROP), is inherited.

45 on of late, namely hydralazine, minocycline, propylthiouracil (PTU) and levamisole-adulterated cocain

46 duced in adult rats by treatment with 0.025% propylthiouracil (PTU) for 6 weeks (PTU-S) and 1 year (P

47 sed to the model thyroid hormone suppressant propylthiouracil (PTU) from < 1 to 30 days post hatch.

48 Propylthiouracil (PTU) is an anti-thyroid drug that repo

49 Propylthiouracil (PTU) is favored over methimazole (MMI)

50 was induced by administration of 3 or 10 ppm propylthiouracil (PTU) to pregnant and lactating dams vi

51 slow skeletal TnI (ssTnI), were treated with propylthiouracil (PTU) to revert MHC expression from adu

52 3)) and thyroxine (T(4))) or inhibitors (6-N-propylthiouracil (PTU), Tetrabromobisphenol A (TBBPA)) o

53 Propylthiouracil (PTU), used to treat Graves' disease, o

54 Four were intolerant of CBZ and received propylthiouracil (PTU), with good effect in 3.

55 We determined if propylthiouracil (PTU)-induced hypothyroidismin hamsters

56 rat hearts containing alpha-MHC isoform and propylthiouracil (PTU)-treated rat hearts containing bet

57 rload (PO), and (2) sustained treatment with propylthiouracil (PTU).

58 tment with the thyroxine synthesis inhibitor propylthiouracil (PTU).

59 dominantly V1 myosin) and those treated with propylthiouracil (PTU; V3 myosin).

60 the synthesis of triiodothyronine (T3) with propylthiouracil rescued pressure overload-induced hyper

61 tion of TH by treating Thrb(PV/PV) mice with propylthiouracil (Thrb(PV/PV)-PTU mice) and compared the

62 n potencies (methimazole, iopanoic acid, and propylthiouracil) to evaluate this linkage.

63 document cases of vasculitis occurring after propylthiouracil treatment.

64 , we validated two new potent derivatives of propylthiouracil, ZINC05626394 (IC50 = 10.81 muM) and ZI